Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its second quarter financial results announcement for Wednesday, December 11, 2024, after market close. The company will host a conference call at 4:30 P.M. EST to discuss the results for the quarter ended October 31, 2024. Investors can join via phone or access the replay through the company's website within 72 hours.
Champions Oncology (NASDAQ:CSBR), un fornitore globale di servizi di ricerca preclinica e clinica specializzato in soluzioni oncologiche, ha programmato l'annuncio dei risultati finanziari del secondo trimestre per mercoledì 11 dicembre 2024, dopo la chiusura dei mercati. L'azienda terrà una conferenza telefonica alle 16:30 EST per discutere i risultati del trimestre conclusosi il 31 ottobre 2024. Gli investitori possono partecipare tramite telefono o accedere alla registrazione attraverso il sito web dell'azienda entro 72 ore.
Champions Oncology (NASDAQ:CSBR), un proveedor global de servicios de investigación preclínica y clínica especializado en soluciones oncológicas, ha programado el anuncio de resultados financieros del segundo trimestre para el miércoles 11 de diciembre de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a las 4:30 P.M. EST para discutir los resultados del trimestre que terminó el 31 de octubre de 2024. Los inversores pueden unirse por teléfono o acceder a la repetición a través del sitio web de la empresa dentro de las 72 horas.
Champions Oncology (NASDAQ:CSBR)는 종양학 솔루션을 전문으로 하는 글로벌 전임상 및 임상 연구 서비스 제공업체로서 2024년 12월 11일 수요일, 시장 종료 후 2분기 재무 결과 발표를 예정하고 있습니다. 회사는 2024년 10월 31일에 끝난 분기의 결과를 논의하기 위해 동부 표준시 기준으로 오후 4시 30분에 전화 회의를 개최합니다. 투자자는 전화로 참여하거나 회사 웹사이트를 통해 72시간 이내에 재생을 이용할 수 있습니다.
Champions Oncology (NASDAQ:CSBR), un fournisseur mondial de services de recherche préclinique et clinique spécialisé dans les solutions d'oncologie, a prévu l'annonce des résultats financiers du deuxième trimestre pour le mercredi 11 décembre 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique à 16h30 EST pour discuter des résultats du trimestre clos le 31 octobre 2024. Les investisseurs peuvent rejoindre par téléphone ou accéder à la rediffusion via le site Web de l'entreprise dans les 72 heures.
Champions Oncology (NASDAQ:CSBR), ein globaler Anbieter von präklinischen und klinischen Forschungsdienstleistungen, der sich auf Onkologie-Lösungen spezialisiert hat, hat die Bekanntgabe der Finanzzahlen für das zweite Quartal für Mittwoch, den 11. Dezember 2024, nach Marktschluss angesetzt. Das Unternehmen wird um 16:30 Uhr EST eine Telefonkonferenz abhalten, um die Ergebnisse für das zum 31. Oktober 2024 abgelaufene Quartal zu besprechen. Investoren können telefonisch teilnehmen oder die Aufzeichnung innerhalb von 72 Stunden über die Website des Unternehmens abrufen.
- None.
- None.
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
SOURCE: Champions Oncology, Inc.
View the original press release on accesswire.com
FAQ
When will Champions Oncology (CSBR) release Q2 2024 earnings?
What time is Champions Oncology (CSBR) Q2 2024 earnings call?
How can I access Champions Oncology (CSBR) Q2 2024 earnings call?
